Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment MilestonePhase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the 600-patient enrollment milestone confirming ABTECT currently on pace to reach full enrollment in early Q1 2025To date, baseline participants baseline characteristics and trial trends in line with observations from Phase 2b trialPARIS, France, August 6, 2024, 8:30 a.m. CEST – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today that in July 2024, the 600th participant was enrolled in the Phase 3 ABTECT Trial. Based on this milestone and current enrollment pace, the Company reaffirms expectations to reach full enrollment in early Q1 2025. An updated version of the Company's corporate presentation reflecting these updates can be found on its website at www.abivax.com.About ObefazimodObefazimod, Abivax's lead investigational drug candidate, is an orally administered small molecule that was demonstrated to potentially enhance the expression of a single microRNA, miR-124. Phase 2 clinical trials in patients with UC have generated positive data, resulting in the initiation of a pivotal global Phase 3 clinical trial program (ABTECT Program), with first patients enrolled in the United States in October 2022. Initiation of a Phase 2b clinical trial in Crohn's disease is expected in Q3 2024, and exploration of potential combination therapy opportunities in UC is ongoing.About AbivaxAbivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's ...Full story available on Benzinga.com

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone PARIS, France, August 6, 2024, 8:30 a.m. CEST – Abivax SA ((Euronext Paris &, NASDAQ: ABVX ) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today that in July 2024, the 600 th participant was enrolled in the Phase 3 ABTECT Trial.

Based on this milestone and current enrollment pace, the Company reaffirms expectations to reach full enrollment in early Q1 2025. An updated version of the Company's corporate presentation reflecting these updates can be found on its website at www.abivax.

com . About Obefazimod Obefazimod, Abivax's lead investigational drug candidate, is an orally administered small molecule that was demonstrated to potentially enhance the expression of a single microRNA, miR-124. Phase 2 clinical trials in patients with UC have generated positive data, resulting in the initiation of a pivotal global Phase 3 clinical trial program (ABTECT Program), with first patients enrolled in the United States in October 2022.

Initiation of a Phase 2b clinical trial in Crohn's disease is expected in Q3 2024, and exploration of potential combination therapy opportunities in UC is ongoing. About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's na.